Understanding the Current Rating
The Strong Sell rating assigned to Mangalam Drugs and Organics Ltd indicates a cautious stance for investors, signalling significant concerns about the company’s financial health and market prospects. This rating is derived from a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment, helping investors understand the risks and challenges associated with the stock.
Quality Assessment
As of 29 September 2026, Mangalam Drugs and Organics Ltd exhibits a below-average quality grade. The company’s long-term fundamental strength remains weak, with a concerning compound annual growth rate (CAGR) of operating profits at -191.73% over the past five years. This steep decline highlights persistent operational challenges and an inability to generate sustainable earnings growth.
Profitability metrics further underscore the quality concerns. The average Return on Equity (ROE) stands at a modest 2.26%, reflecting low profitability relative to shareholders’ funds. Additionally, the company’s ability to service its debt is poor, with an average EBIT to interest coverage ratio of -0.67, indicating that operating earnings are insufficient to cover interest expenses. These factors collectively point to structural weaknesses in the company’s financial foundation.
Valuation Considerations
The valuation grade for Mangalam Drugs and Organics Ltd is classified as risky. The stock currently trades at valuations that are unfavourable compared to its historical averages, signalling potential overvaluation relative to its earnings and cash flow generation capacity. This is compounded by the company’s negative EBITDA of ₹-9.09 crores, which raises concerns about operational cash flow and the sustainability of its business model.
Investors should note that the stock’s price performance over the past year has been poor, with a return of -57.26%. This significant decline reflects market apprehension about the company’s prospects and the risks embedded in its valuation. The risky valuation grade suggests that the stock may not offer adequate margin of safety for investors seeking stable returns.
Financial Trend Analysis
The financial trend for Mangalam Drugs and Organics Ltd is currently flat, indicating stagnation in key financial metrics. The company reported flat results in the half-year ended June 2026, with a Return on Capital Employed (ROCE) at a low -15.53%, signalling inefficient use of capital and poor operational returns.
Debt metrics also raise red flags. The debt-to-equity ratio stands at 1.02 times, the highest level recorded in the recent half-year period, suggesting elevated leverage and increased financial risk. Moreover, the debtors turnover ratio is at a low 5.76 times, indicating slower collection of receivables and potential liquidity pressures.
Profitability has deteriorated sharply, with profits falling by 296.6% over the past year. This steep decline in earnings, coupled with negative EBITDA, highlights the company’s ongoing struggles to generate positive cash flows and maintain financial stability.
Technical Outlook
From a technical perspective, the stock is mildly bearish. Recent price movements show a 1-day decline of -0.13%, a 1-week drop of -4.48%, and a 1-month decrease of -3.01%. Although there has been some recovery over the 3- and 6-month periods with gains of 8.95% and 8.87% respectively, the overall trend remains weak, especially when considering the year-to-date return of 12.11% is overshadowed by a 1-year loss of -57.26%.
The consistent underperformance against the BSE500 benchmark over the last three years further emphasises the stock’s technical challenges. This persistent lag indicates limited investor confidence and a lack of sustained upward momentum in the share price.
Implications for Investors
The Strong Sell rating on Mangalam Drugs and Organics Ltd serves as a cautionary signal for investors. It reflects a combination of weak fundamentals, risky valuation, stagnant financial trends, and a bearish technical outlook. Investors should carefully consider these factors before initiating or maintaining positions in the stock, as the risks currently outweigh potential rewards.
For those holding the stock, it may be prudent to reassess portfolio exposure given the company’s ongoing operational and financial challenges. Prospective investors should seek alternative opportunities with stronger fundamentals and more favourable risk-return profiles within the Pharmaceuticals & Biotechnology sector or broader market.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Sector and Market Context
Mangalam Drugs and Organics Ltd operates within the Pharmaceuticals & Biotechnology sector, a space that generally demands strong research and development capabilities, regulatory compliance, and robust financial health to sustain growth. Compared to its peers, the company’s microcap status and weak financial metrics place it at a disadvantage in attracting investor interest and capital.
While the broader sector has seen pockets of innovation and growth, Mangalam Drugs and Organics Ltd’s persistent underperformance and financial strain highlight the challenges faced by smaller players in maintaining competitiveness and operational efficiency.
Summary of Key Metrics as of 29 September 2026
- Market Capitalisation: Microcap segment
- Mojo Score: 17.0 (Strong Sell)
- Quality Grade: Below Average
- Valuation Grade: Risky
- Financial Grade: Flat
- Technical Grade: Mildly Bearish
- 1-Year Stock Return: -57.26%
- Operating Profit CAGR (5 years): -191.73%
- Average ROE: 2.26%
- EBIT to Interest Coverage Ratio: -0.67
- Debt-to-Equity Ratio (HY): 1.02 times
- ROCE (HY): -15.53%
- EBITDA: ₹-9.09 crores
These figures collectively reinforce the rationale behind the current Strong Sell rating and provide a comprehensive picture of the company’s financial and operational standing.
Conclusion
In conclusion, Mangalam Drugs and Organics Ltd’s Strong Sell rating by MarketsMOJO, last updated on 19 May 2025, remains justified when considering the company’s current financial and market position as of 29 September 2026. The combination of weak quality metrics, risky valuation, flat financial trends, and bearish technical signals suggests that investors should approach this stock with caution. Monitoring ongoing developments and sector dynamics will be essential for any future reassessment of the company’s investment potential.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
